Intended for healthcare professionals


Controversial disease dropped from Prozac product information

BMJ 2004; 328 doi: (Published 12 February 2004) Cite this as: BMJ 2004;328:365
  1. Ray Moynihan
  1. Washington, DC

    The drug manufacturer Lilly has been forced to drop one of the disorders it had previously listed for its antidepressant drug fluoxetine (Prozac), following a finding by the European drug regulator that the condition was not a well-established disease entity.

    Some health researchers welcomed the regulator's decision, saying premenstrual dysphoric disorder (PMDD), which was only recently described, was an invented illness and a strong example of the medicalisation of ordinary life.

    “I think it's a wonderful decision” says Paula Caplan, a psychologist adjunct and professor at Brown University, Rhode Island. “This kind of scrutiny of the science or …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription